Stockscreener 앱 받기
0.4714
4.22%
0.0191
시간 외 거래:
.47
-0.0014
-0.30%
전일 마감가:
$0.4523
열려 있는:
$0.4614
하루 거래량:
199.89K
Relative Volume:
0.40
시가총액:
$13.20M
수익:
-
순이익/손실:
$-55.73M
주가수익비율:
-0.1461
EPS:
-3.2274
순현금흐름:
$-68.87M
1주 성능:
+1.53%
1개월 성능:
-44.55%
6개월 성능:
-72.59%
1년 성능:
-91.29%
1일 변동 폭
$0.4412
$0.4913
1주일 범위
$0.4308
$0.5205
52주 변동 폭
$0.42
$7.19
Jasper Therapeutics Inc Stock (JSPR) Company Profile
명칭
Jasper Therapeutics Inc
전화
(650) 549-1400
주소
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
0.4714 | 13.45M | 0 | -55.73M | -68.87M | -3.2274 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 재개 | UBS | Neutral |
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-07-08 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-09-09 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-08 | 개시 | BTIG Research | Buy |
| 2024-06-27 | 개시 | Stifel | Buy |
| 2024-05-06 | 개시 | H.C. Wainwright | Buy |
| 2024-04-03 | 개시 | Evercore ISI | Outperform |
| 2024-03-28 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-18 | 개시 | TD Cowen | Outperform |
| 2023-08-11 | 개시 | CapitalOne | Overweight |
| 2022-02-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 개시 | Credit Suisse | Outperform |
| 2021-10-21 | 개시 | William Blair | Outperform |
| 2021-10-20 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-13 | 개시 | Oppenheimer | Outperform |
모두보기
Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스
Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 virtual meeting, board and pay votes - Stock Titan
Jasper Therapeutics (JSPR) Edges Lower, Testing Key Support Near $0.44Seasonality Effect - newsline.com
Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Nasdaq warns Jasper Therapeutics (JSPR) on sub-$1 bid, delisting risk noted - Stock Titan
Jasper Therapeutics (JSPR) Edges Higher Amid Tight Trading RangeAndrews Pitchfork - newsline.com
symbol__ Stock Quote Price and Forecast - CNN
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long John Silver's Franchisee To Liquidate - Dailyhunt
JSPR Q1 2026 Earnings: Massive EPS Beat with -$0.04 vs -$0.4965 Estimate; Stock RisesEarnings Power Value - newsline.com
Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long - Benzinga
Bears are losing control over Jasper Therapeutics (JSPR), here's why it's a 'buy' now - MSN
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now - sharewise.com
Jasper Therapeutics Initiates Review of Strategic Alternatives to Maximize Shareholder Value - marketscreener.com
Jasper Therapeutics Explores Sale, Merger and Other Strategic Alternatives - Moomoo
Jasper Therapeutics Weighs Sale as Cash Dwindles, Drug's Fate Uncertain - BriefGlance
Jasper Therapeutics Initiates Strategic Alternatives Review to Maximize Shareholder Value Amid Mast Cell Disease Therapy Focus 1 - Minichart
Jasper Therapeutics Launches Strategic Alternatives Review Amid Uncertainty - TipRanks
Jasper Therapeutics explores strategic alternatives By Investing.com - Investing.com South Africa
Jasper Therapeutics explores strategic alternatives - Investing.com
Jasper Therapeutics begins strategic review to maximize shareholder value - TradingView
Jasper Therapeutics (NASDAQ: JSPR) weighs sale, merger or wind-down options - Stock Titan
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value - GlobeNewswire
JSPR Q1 2026 Earnings: Surprise EPS Beat Overshadowed by Broader HeadwindsAnnual Financial Report - The Legal Advocate
JSPR Q1 2026 Earnings: Narrowed Loss Surpasses Estimates, Stock Slides Despite ProgressProduct Revenue Analysis - newsline.com
Jasper Therapeutics (JSPR) Hovers Near Support as Biotech Sentiment Remains CautiousWave Equality - The Legal Advocate
Jasper Therapeutics (JSPR) Edges Higher: Small-Cap Biotech Tests Resistance at $0.95ETF Flow - The Legal Advocate
Jasper Therapeutics (JSPR) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock Higher - The Legal Advocate
Jasper Therapeutics Announces Board Resignation and Committee Change - TipRanks
Christian Nolet resigns from Jasper Therapeutics board; Svetlana Lucas joins Audit Committee - TradingView
Jasper Therapeutics (NASDAQ: JSPR) reports director exit and audit change - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionGeovax Labs (NASDAQ:GOVX), Jasper Therapeu - Benzinga
Jasper Therapeutics, Inc.Class A Common Stock (NQ: JSPR - The Chronicle-Journal
Jasper Therapeutics stock maintains outperform rating at Citizens By Investing.com - Investing.com Canada
JSPR Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Hold Rating, Cuts Target Price to $3 - Moomoo
JSPR Maintained by RBC Capital -- Price Target Lowered to $3.00 - GuruFocus
RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk - Moomoo
TD Cowen Downgrades Jasper Therapeutics(JSPR.US) to Hold Rating - Moomoo
TD Cowen downgrades Jasper Therapeutics stock rating to Hold By Investing.com - Investing.com Canada
Jasper Therapeutics, Inc. Stock 12‑Month Price Target Cut to $9.08, Implies 847% Upside - TradingView
Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss - MSN
Jasper Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
[10-Q] Jasper Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Jasper drug sees 67% complete response in CSU trial update - Stock Titan
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Jasper Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Jasper Therapeutics (NASDAQ: JSPR) cuts Q1 2026 loss but flags funding risk - Stock Titan
Jasper Therapeutics (JSPR) price target decreased by 13.33% to 7.73 - MSN
Morgan Stanley units report sub‑5% stakes in Jasper Therapeutics (JSPR) - Stock Titan
TradingKey - TradingKey
Jasper Therapeutics Inc (JSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Jasper Therapeutics Inc 주식 (JSPR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lucas Svetlana | Director |
Sep 22 '25 |
Buy |
2.43 |
20,000 |
48,600 |
20,000 |
| MARTELL RON | President and CEO |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
74,118 |
| Shizuru Judith Anne | Director |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
156,901 |
2.60%
0.94%
자본화:
|
볼륨(24시간):